RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
RELMADA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.16+0.06 (+1.94%)
Close on Oct 19, 2026
- Market cap
- $355.11M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.15 (+57.21%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $355.11M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.72
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$61.93M
- EPS, diluted
- -$0.96
- Book value per share
- $1.84
- Diluted shares
- 112M
Twelve years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
-$65.13M
Net income
-$61.93M
EPS, diluted
-$0.96
Free cash flow
–
Reported periodTrailing twelve months